Sprague Resources LP (NYSE:SRLP) shares decreased -0.12% in last trading session and ended the day at $24.44. SRLP Gross Margin is 7.10% and its has a return on assets of 9.40%. Sprague Resources LP (NYSE:SRLP) quarterly performance is 4.03%.
Zacks upgraded shares of Sprague Resources (NYSE:SRLP) from a hold rating to a strong-buy rating in a research report report published on Monday, AnalystRatings.NET reports. The firm currently has $27.00 price objective on the stock.
Proofpoint, Inc. (NASDAQ:PFPT) ended the last trading day at $55.41. Company weekly volatility is calculated as 4.47% and price to cash ratio as 5.40. Proofpoint, Inc. (NASDAQ:PFPT) showed a weekly performance of -0.61%.
Proofpoint, Inc. (NASDAQ: PFPT) reported Q3 EPS of ($0.06), $0.05 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $69.1 million versus the consensus estimate of $66.01 million. Proofpoint, Inc. sees Q4 2015 EPS of ($0.12)-($0.11), versus the consensus of ($0.10). Proofpoint, Inc. sees Q4 2015 revenue of $72.5-73.5 million, versus the consensus of $70.6 million. Proofpoint, Inc. sees FY2015 EPS of ($0.36)-($0.35), versus the consensus of ($0.39). Proofpoint, Inc. sees FY2015 revenue of $263.0-264.0 million, versus the consensus of $258.0 million.
On 21 October, NanoString Technologies, Inc. (NASDAQ:NSTG) shares increased 0.53% and was closed at $15.24. NSTG EPS growth in last 5 year was 40.20%. NanoString Technologies, Inc. (NASDAQ:NSTG) year to date (YTD) performance is 9.40%.
NanoString Technologies, Inc. (NASDAQ:NSTG), announced that the company will release third quarter 2015 financial results after the close of trading on Monday, November 2, 2015. Company management will host a conference call beginning at 4:30pm ET to discuss those results and to provide a business update.
Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) shares increased 12.82% in last trading session and ended the day at $5.28. NWBO has a return on assets of -354.70%. Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) quarterly performance is -56.86%.
Northwest Biotherapeutics Inc. (NASDAQ:NWBO) announced that the Company has entered into agreement for funding of $30 million from Woodford Investment Management in the UK (“Woodford”). Woodford will purchase $30 million of the Company’s common stock at $5.50 per share, for a total of 5,454,545 shares, raising Woodford’s total holdings to 25,915,937 shares, or about 28.1% of the Company. The purchase will take place in a closing on or before October 22, 2015.
Medivation, Inc. (NASDAQ:MDVN) caters to the Healthcare space. It has a net profit margin of 34.00% and weekly performance is 3.38%. On the last day of trading company shares ended up at $43.17. Medivation, Inc. (NASDAQ:MDVN) distance from 50-day simple moving average (SMA50) is -4.65%.
On October 6, 2015, Medivation, Inc. (NASDAQ:MDVN) completed its acquisition of all rights to talazoparib (MDV3800; formerly referred to as BMN-673) from BioMarin Pharmaceutical Inc. (“BioMarin”) pursuant to the Asset Purchase Agreement entered into between Medivation and BioMarin dated August 21, 2015 (the “Agreement”). The acquired talazoparib assets include all patents, data, know-how, third party agreements, regulatory materials and inventories. Medivation also assumes certain liabilities related to the acquired assets to the extent they arise after the closing, including liabilities for the ongoing clinical trials of talazoparib, liabilities under certain agreements previously entered into by BioMarin and assigned to Medivation in the transaction, and certain of BioMarin’s obligations pursuant to its Stock Purchase Agreement with LEAD Therapeutics, Inc., dated February 4, 2010, as amended, the agreement under which BioMarin initially acquired BMN-673.
Leave a Reply